02  ·  Monthly Pulse

Supplement Market Pulse

Top signals across five segments, framed for consultant use. Evidence quality, trend velocity, and the so-what — updated monthly by Brendan Walsh.

Edition 02  ·  May 2026

May 2026
Global market size
$203B
↑ 9.1% CAGR to 2030
Hottest segment
Gut health
↑ 7.3% yr  ·  +$4.7B by 2028
Ingredient of the month
Berberine
↑ 108K Amazon searches / week
Regulatory watch
NMN  ·  EU
Novel food auth. pending
Top five signals this month Ranked by consultant relevance
01
Women's health Cross-segment
Berberine hits 108K+ weekly Amazon searches — GLP-1 halo driving unsustainable claim inflation

Consumer demand surging on "nature's Ozempic" narrative. Brands stacking berberine with Akkermansia, cinnamon, and chromium into GLP-1 labelled products at $80+/mo — versus $15–30 for quality single-ingredient. Clinical weight loss reality: 2–4kg versus 10%+ for prescription GLP-1.

So what: Claim enforcement risk is building. Advise brand clients to migrate toward defensible PCOS / metabolic health positioning now, before FTC attention intensifies.
Tier 1FTC — Health Products Compliance Guidance
Tier 1PubMed — Berberine weight loss RCT evidence
Tier 2NutraIngredients USA — Berberine GLP-1 claim landscape

Consumer search and social signals also inform velocity rating.

Velocity
02
Gut health Women's health
Postbiotics cross into perimenopause — gut-hormone axis becomes the formulation theme

Strain-specific Lactobacillus for vaginal health combined with postbiotic formats (heat-killed Akkermansia) converging in women's health launches. Timeline's Mitopure gummies extending the postbiotic concept into longevity crossover territory.

So what: The gut-hormone-perimenopause triangle is the most defensible multi-benefit narrative in women's health right now. Watch for new brand entrants in H1 2026.
Tier 1PubMed — Postbiotics and women's health research
Tier 2NutraIngredients — Postbiotic category momentum

Consumer search and social signals also inform velocity rating.

Velocity
03
Vitamins & minerals
GLP-1 medication reshaping vitamins demand — B-complex and D3/K2 gaining new adjacency

27% of Americans with weight-loss goals plan GLP-1 use in 2026. Appetite suppression creating real nutrient gap demand — B-complex, iron, D3/K2, magnesium all cited as GLP-1 companion supplements. Clarkston Consulting flagging this as a structural demand shift.

So what: "GLP-1 companion" is an emerging and defensible product sub-category with a better evidence base than direct GLP-1 mimicry claims. Advise clients to move here.
Tier 2Clarkston Consulting — GLP-1 companion supplement analysis
Tier 2NutraIngredients USA — GLP-1 vitamins demand shift

Consumer search and social signals also inform velocity rating.

Velocity
04
Vitamins & minerals GLP-1 adjacency
GLP-1 companion category crosses from trend to infrastructure — 124% CAGR and major brand entry confirm structural shift

Innova Market Insights confirms products making GLP-1-related claims have risen 124% CAGR over five years, with North America accounting for 83% of growth. Danone launched Oikos Fusion specifically for GLP-1 users. HTBA unveiled Leanara at Vitafoods Europe 2026 — a GLP-1 companion ingredient combining citrus bioflavonoids and bioavailable B12 to address lean muscle loss. GNC published data showing GLP-1 users are deficient in calcium, iron, magnesium, potassium, and vitamins A, C, D, E, and K.

So what: The first-mover branded supplement stack at mass market scale is still unoccupied. Nestle and Danone are entering via functional food — not supplement. The pure supplement stack opportunity is open. Move in Q3 2026 or cede it.
Velocity
Tier 2Nutrition Insight — GLP-1 companion 124% CAGR, brand entry
Tier 2Nutrition Insight — HTBA Leanara launch, Vitafoods 2026
Tier 2NutraIngredients — GLP-1 nutrient deficiency data (GNC)

Consumer search and social signals also inform velocity rating.

05
Women's health
Creatine for women becomes the best-evidenced opportunity in women's health supplements — perimenopause RCT pipeline accelerating

The CONCRET-MENOPA RCT confirmed medium-dose creatine hydrochloride superior to placebo for reaction time in perimenopausal and menopausal women. A St. Olaf College study showed improvements in sleep quality, body composition, cognitive function, and muscle strength after 14 weeks. A third trial (PERIHIRT) is now actively recruiting at UNC Chapel Hill. SPINS named creatine one of four 2026 ingredients to watch alongside ashwagandha, colostrum, and protein.

So what: Creatine for women is now the most evidence-dense opportunity in the women's health supplement segment. The cognitive and perimenopause angle is clinically defensible and commercially unoccupied at premium scale. The evidence pipeline is only getting stronger — move now.
Velocity
Tier 1ClinicalTrials.gov — CONCRET-MENOPA RCT
Tier 1Journal of American Nutrition Association — CONCRET-MENOPA results
Tier 1ClinicalTrials.gov — PERIHIRT trial (recruiting)
Tier 2Nutritional Outlook / SPINS — 2026 ingredients to watch

Consumer search and social signals also inform velocity rating.

Ingredients to watch
Psychobiotics
LP815 / GABA-producing strains. Gut-brain-mood axis. Human RCTs thin but pipeline active for 2026–27. Category-defining window open.
Urolithin A
Mitopure RCT data strong (12% muscle strength, 16 wks). Gummy format launch Feb 2026 moving from clinical to mainstream longevity.
Shatavari
Ayurvedic hormonal adaptogen. Western clinical validation building. PCOS + perimenopause SKUs emerging from specialist brands.
Dihydroberberine
Enhanced bioavailability berberine metabolite. Toniiq leading. Premium metabolic health positioning without the standard form's GI tolerability issues.
Regulatory radar
WatchNMN — EU novel food application under assessment. UK FSA monitoring unauthorised anti-aging and cellular repair claims.
WatchBerberine / GLP-1 claims — FTC updated Health Products Compliance Guidance applies. "Nature's Ozempic" framing is unsubstantiated disease claim territory.
MonitorCRN drug preclusion reform proposal (Mar 2026) — industry pushing to end regulatory uncertainty on supplement-drug overlap ingredients.
StableTurmeric adulteration study: 22% of products contain undeclared ingredients. Quality certification narrative strengthened.